Navigation Links
AspenBio Pharma Announces Closing of Public Offering of 1,946,000 Shares of Common Stock

CASTLE ROCK, Colo., Nov. 20, 2012 /PRNewswire/ -- AspenBio Pharma, Inc. (Nasdaq: APPY), an in vitro diagnostic company, today announced the closing of an underwritten public offering of 1,946,000 shares of common stock at an offering price of $2.10 per share. After underwriting discounts and commissions and estimated offering expenses, the Company received net proceeds from the offering of approximately $3.7 million. AspenBio Pharma has also granted the underwriters a 45-day option to purchase up to an additional 291,900 shares of common stock to cover over-allotments, if any.

AspenBio intends to use the net proceeds from this offering for general corporate purposes, including conducting a clinical trial for its blood-based appendicitis test and for working capital purposes.

Aegis Capital Corp. acted as the sole book-running manager for the offering.

A registration statement on Form S-3 relating to the shares was filed with the Securities and Exchange Commission and was declared effective on July 27, 2011. A final prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC's web site at Copies of the final prospectus may be obtained from the offices of Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email:, or from the above-mentioned SEC website.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About AspenBio Pharma and AppyScore

AspenBio Pharma, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its blood-based appendicitis test. The unique appendicitis test has projected high sensitivity and negative predictive value and is designed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management. The test is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging. For more information, visit

Forward-Looking Statements

This press release includes "forward-looking statements" of AspenBio Pharma, Inc. ("AspenBio") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that AspenBio believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors AspenBio believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of AspenBio. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for AppyScore required for FDA submission, obtain FDA clearance or approval, complete and obtain CE Mark, cost effectively manufacture and generate revenues from AppyScore, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, AspenBio does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in AspenBio's recent filings with the SEC, including its Form 10-Q for the period ended September 30, 2012, filed on November 7, 2012.

For Investors & Media:
Joshua Drumm, Ph.D. / Jason Rando
Tiberend Strategic Advisors, Inc.
(212) 827-0020

SOURCE AspenBio Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AspenBio Pharma Announces Pricing of Public Offering of 1,476,000 Shares of Common Stock
2. AspenBio Pharma Announces Proposed Public Offering
3. AspenBio Pharma Begins Training Hospital Sites for Pivotal Clinical Trial
4. AspenBio Pharma to Provide Shareholders with Business Update
5. AspenBio Pharma Executes Worldwide License Agreement for its Animal Health Assets
6. AspenBio Pharma Engages Tiberend Strategic Advisors as Investor and Public Relations Agency of Record
7. Sihuan Pharmaceutical Collaborates with NeuroVive to Develop Two Innovative Cardio-cerebral Vascular Products in China
8. Ohr Pharmaceutical Announces Additions to Ophthalmic Scientific Advisory Board
9. Isis Pharmaceuticals To Present At The 24th Annual Piper Jaffray Healthcare Conference
10. ShangPharma Announces Third Quarter 2012 Results
11. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
Post Your Comments:
(Date:10/13/2015)... -- Synapse Biomedical Inc. ( ) reported today that ... use of the NeuRx ® Diaphragm Pacing System ... the United States and patient ... PAS study group met their initial enrollment goal ahead ... expanded the enrollment target to 150 participants.   ...
(Date:10/13/2015)... DUBLIN , Oct. 13 2015 ... addition of the "US & European markets ... report to their offering. --> ... "US & European markets for Meniscal Repair - ... --> Research and Markets ( ...
(Date:10/13/2015)... , Oct. 9, 2015 Research and Markets ... "Kombucha Market by Types (Bacteria, Yeast, Mold, Others), ... Mangoes, Flowers, Others), & by Region - Forecasts to ... --> --> The ... last few years. In terms of value, the market ...
Breaking Medicine Technology:
(Date:10/13/2015)... , ... October 13, 2015 , ... The documentary ... Laemmle Music Hall in Beverly Hills October 2 - 8, coinciding with National Hereditary ... Award® consideration, the film takes us through the lives of women - and men ...
(Date:10/13/2015)... ... 13, 2015 , ... The added calories and sugar in an average trick-or-treat ... a parent to do? Registered dietitians from Retrofit , the leading corporate weight ... year. , “Halloween is a high-calorie holiday,” said Dara Aronow, Registered Dietitian, Retrofit. ...
(Date:10/13/2015)... WEST LAFAYETTE, Ind. (PRWEB) , ... October 13, ... ... to establish a new Pillars of Excellence in the Life Sciences Initiative aimed ... part of Purdue’s recently announced $2 billion “Ever True” capital campaign. , The ...
(Date:10/13/2015)... ... October 13, 2015 , ... Vision Group Holdings, the largest LASIK provider in ... brands including The LASIK Vision Institute and TLC Laser Eye Centers, Vision Group Holdings ... laser vision correction. , Global Laser Vision will continue to operate in San Diego ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... enterprise focused on cancer patients, today announced a new partnership with the ... battling this rare type of non-Hodgkin’s lymphoma, their families and physicians. , ...
Breaking Medicine News(10 mins):